Mandashi makes follow on investment in rare cancer firm
Mandashi is pleased to announce a follow on investment in Rarecan. Rarecan believes people with rare cancer have the right to live better, longer lives. They make this happen by bringing people together to create opportunities to accelerate research.
Rarecan is developing a modern digital platform through which people with rarer forms of cancer will be able to share their data with researchers to speed up the discovery of new diagnostics and treatments.
Dr Evans, Director for Mandashi, said: "We're very pleased to be making a follow on investment in Rarecan. Over the last 6 months they have built the foundation of a great business, have grown their patient community enormously, and have put in place a commercial framework we are confident will lead to great success in the future".